A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3.
David Shultz
No relevant relationships to disclose
Jonathan Pai
No relevant relationships to disclose
Madeline Sydney Graber
No relevant relationships to disclose
Gregory M. Heestand
No relevant relationships to disclose
Daniel Tandel Chang
No relevant relationships to disclose
Wendy R. Parulekar
No relevant relationships to disclose
Dongsheng Tu
No relevant relationships to disclose
Malcolm J. Moore
No relevant relationships to disclose
Albert Koong
No relevant relationships to disclose